Jump to Navigation

Resources

  • VillageHealth has no financial arrangements with other organizations to advertise, market or promote products or services. 
  • VillageHealth does not advertise, market or promote specific products or services to patients or providers.

 

Statement of Practitioner Support - Provider Rights and Responsibilities

VillageHealth is committed to partnering with healthcare practitioners to deliver high quality care to plan members. As part of this commitment, our goal is to ensure open, timely communication with practitioners. Although specific areas of support are outlined below, practitioners can contact the VillageHealth Medical Director, VillageHealth Nurse and other VillageHealth staff at 1-800-767-0063 about any issue. You can also visit us on the web at www.villagehealthdm.com.

  1. Program Information. During the implementation process, VillageHealth will provide information about its programs and services, assigned staff, staff qualifications, and contractual relationships. Following the implementation process, this information will be available by request at any time.
  2. Program Participation. Unless otherwise stated in their agreement with the health plan, practitioners may opt out of program participation.
  3. Coordination of patient care. VillageHealth will make sure the practitioner knows which VillageHealth staff is primarily responsible for day-to-day care coordination of the practitioner’s patients. VillagheHealth will send the practitioner a written care plan for each patient followed by updates regarding specific issues encountered during implementation of the plan. The practitioner will also receive regular reports showing patient outcomes compared with regional and national benchmarks.
  4. Contact information for primary VillageHealth support staff. VillageHealth will provide the practitioner with the contact information for the nurse responsible for managing and communicating with the practitioner’s patients. VillageHealth nursing staff can be reached 24 hours per day, 7 days per week.
  5. Decision making support. VillageHealth will actively support the practitioner in making decisions interactively with their patients. This includes provision of a written care plan, episodic issues reports, and quarterly outcomes reports to the provider.
  6. Professional conduct. VillageHealth employees provide courteous service and respectful treatment for practitioners, their staff, and their patients.
  7. Complaint resolution. VillageHealth will provide clear, timely resolution of any practitioner issues. Practitioners can raise issues either by calling 1-800-767-0063 or by addressing correspondence to the address below:

             VillageHealth Disease Management
             Three Hawthorn Parkway, Suite 410
              Vernon Hills, IL 60061 


 VillageHealth Disease Management

Clinical Practice Guideline/Clinical Practice Recommendation

SUMMARY TABLE
ITEM # TITLE CKD Stage 3-5 not on dialysis CKD Stage 5 on dialysis

1.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification

 

2.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access

3.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

4.

National Kidney Foundation. KDOQITM Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target (excluding CPR 2.1.2)

5.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines for Nutrition in Chronic Renal Failure.

6.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease

7.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease (excluding CPG 1.4, 3.2, & 6.5)

8.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

9.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients

 

10.

National Kidney Foundation. KDOQI TM Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease(excluding CPG 2)

11.

Renal Physicians Association Clinical Practice Guideline #2

Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis, February 2000

12.

Renal Physicians Association Clinical Practice Guideline #3; Appropriate Patient Preparation for Renal Replacement Therapy

 

13.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule

14.

FDA EPOGEN® (Epoetin alfa) FOR INJECTION package insert

15.

Suma Dronovalli, Basil Burney, George Bakris. Glycemic Control and Cardiovascular Disease in Chronic Kidney Disease

16.

KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)


DETAILED TABLE

1.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39:S1-S000, 2002 (suppl 1)  http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm

Stages 3-5

(not on dialysis)

Figures
Tables
Acronyms and abbreviations
K/DOQI advisory board members
Work group and evidence review team membership and support group

Foreword

Part 1. Executive Summary

Part 2. Background

Part 3. Chronic kidney disease as a public health problem

Part 4. Definition and classification of stages of chronic kidney disease

Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease

Part 6. Association of level of GFR with complications in adults

  • Guideline 7. Association of Level of GFR With Hypertension
  • Guideline 8. Association of Level of GFR With Anemia
  • Guideline 9. Association of Level of GFR With Nutritional Status
  • Guideline 10. Association of Level of GFR With Bone Disease and Disorders of Calcium and Phosphorus Metabolism
  • Guideline 11. Association of Level of GFR With Neuropathy
  • Guideline 12. Association of Level of GFR With Indices of Functioning and Well-Being

Part 7. Stratification of risk for progression of kidney disease and development of cardiovascular disease

  • Guideline 13. Factors Associated With Loss of Kidney Function in Chronic Kidney Disease
  • Guideline 14. Association of Chronic Kidney Disease With Diabetic Complications
  • Guideline 15. Association of Chronic Kidney Disease With Cardiovascular Disease

Part 8. Recommendations for clinical performance measures

Part 9. Approach to chronic kidney disease using these guidelines

Part 10. Appendices

  • Appendix 1. Methods for Review of Articles
  • Appendix 2. Kidney Function and Associated Conditions in the United States: Methods and Findings From the Third National Health and Nutrition Examination Survey (1988 to 1994)
  • Appendix 3. Methodological Aspects of Evaluating Equations to Predict GFR and Calculations Using 24-Hour Urine Samples

Part 11. Work group members

Part 12. Acknowledgements

Bibliography

Disclaimer

2.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. Am J Kidney Dis 48:S1-S322, 2006

(suppl 1).  http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm

Stage 5

(on dialysis)

CLINICAL PRACTICE GUIDELINES FOR HEMODIALYSIS ADEQUACY, UPDATE 2006 
Hemodialysis Adequacy 2006 Work Group Membership
Tables and Figures
Abbreviations and Acronyms
Foreword
Introduction

Appendix.  Methods for Adding Residual Clearance to Hemodialyzer Clearance
Work Group Biographies
References

Abbreviations and Acronyms
Appendix 1. Methods for Evaluating Evidence
Appendix 2. Medline Search Strategies
Disclaimer

Stage 5

(on dialysis)

CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY, UPDATE 2006 

Peritoneal Dialysis Adequacy 2006 Work Group Membership
Tables
Abbreviations and Acronyms
Foreword
Introduction

Work Group Biographies
References

Abbreviations and Acronyms
Appendix 1. Methods for Evaluating Evidence
Appendix 2. Medline Search Strategies
Disclaimer

All Stages

CLINICAL PRACTICE GUIDELINES FOR VASCULAR ACCESS, UPDATE 2006  
Vascular Access 2006 Work Group Membership
Tables and Figures
Abbreviations and Acronyms
Glossary
Foreword
Introduction

Work Group Biographies
References

Abbreviations and Acronyms
Appendix 1. Methods for Evaluating Evidence
Appendix 2. Medline Search Strategies
Disclaimer

3.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47:S1-S146, 2006 (suppl 3).  http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm

All Stages

Tables
Figures
Abbreviations and Acronyms
Work Group Membership
KDOQI Advisory Board Members
Foreword

  • I: Executive Summary
  • II: Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults
    • 1.1. Identifying Patients and Initiating Evaluation
    • 1.2. Evaluation of Anemia in CKD
    • 2.1. Hb Range
    • 3.1. Using ESAs
    • 3.2. Using Iron Agents
    • 3.3. Using Pharmacological and Nonpharmacological Adjuvants to ESA Treatment in HD-CKD
    • 3.4. Transfusion Therapy
    • 3.5. Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb
  • III: Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Children
    • 1.1. Identifying Patients and Initiating Evaluation
    • 1.2. Evaluation of Anemia in CKD
    • 2.1. Hb Range
    • 3.1. Using ESAs
    • 3.2. Using Iron Agents
    • 3.3. Using Pharmacological and Nonpharmacological Adjuvants to ESA Treatment in HD-CKD
    • 3.4. Transfusion Therapy
    • 3.5. Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb Level
  • IV: Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Transplant Recipients
  • V:  Appendix 1: Methods of Evidence Review and Synthesis

Work Group Biographies
Acknowledgments
References
Disclaimer

4.

KDOQITM Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target  http://www.kidney.org/professionals/kdoqi/guidelines_anemiaUP/index.htm

All Stages

Work Group Membership
K/DOQI™ Advisory Board Members
Tables and Figures

Anemia Update Methods
Appendix 1. Comparison of FDA-Approved Prescribing Information for Epoetin Alfa and KDOQI Anemia Guidelines
Biographical and Disclosure Information
References

5.

National Kidney Foundation. KDOQITM Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. American Journal of Kidney Diseases, June 2000  http://www.kidney.org/professionals/KDOQI/guidelines_updates/doqi_nut.html

All Stages

I. ADULT GUIDELINES

A. Maintenance Dialysis

1.  Evaluation of Protein-Energy Nutritional Status

Guideline 1. Use of Panels of Nutritional Measures

Guideline 2. Panels of Nutritional Measures for Maintenance Dialysis Patients

Guideline 3. Serum Albumin

Guideline 4. Serum Prealbumin

Guideline 5. Serum Creatinine and the Creatinine Index

Guideline 6. Serum Cholesterol

Guideline 7. Dietary Interviews and Diaries

Guideline 8. Protein Equivalent of Total Nitrogen Appearance (PNA)

Guideline 9. Subjective Global Nutritional Assessment (SGA)

Guideline 10. Anthropometry

Guideline 11. Dual Energy X-Ray Absorptiometry (DXA)

Guideline 12. Adjusted Edema-Free Body Weight (aBWef)

2.  Management of Acid-Base Status

Guideline 13. Measurement of Serum Bicarbonate

Guideline 14. Treatment of Low Serum Bicarbonate

3.  Management of Protein and Energy Intake

Guideline 15. Dietary Protein Intake (DPI) in Maintenance Hemodialysis (MHD)

Guideline 16. Dietary Protein Intake (DPI) for Chronic Peritoneal Dialysis (CPD)

Guideline 17. Daily Energy Intake for Maintenance Dialysis Patients

4.  Nutritional Counseling and Follow-Up

Guideline 18. Intensive Nutritional Counseling With Maintenance Dialysis (MD)
Guideline 19. Indications for Nutritional Support
Guideline20. Protein Intake During Acute Illness
Guideline 21. Energy Intake During Acute Illness

5. Carnitine

Guideline 22. L-Carnitine for Maintenance Dialysis Patients

B. Advanced Chronic Renal Failure Without Dialysis

Guideline 23. Panels of Nutritional Measures for Nondialyzed Patients
Guideline 24. Dietary Protein Intake for Nondialyzed Patients
Guideline 25. Dietary Energy Intake (DEI) for Nondialyzed Patients

Guideline 26. Intensive Nutritional Counseling for Chronic Renal Failure (CRF)
Guideline 27. Indications for Renal Replacement Therapy

  C. Appendices (Adult Guidelines)

Appendix I. Methods for Measuring Serum Albumin

Appendix II. Methods for Calculation and Use of the Creatinine Index

Appendix III. Dietary Interviews and Diaries

Appendix IV. Role of the Renal Dietitian

Appendix V. Rationale and Methods for the Determination of the Protein Equivalent of Nitrogen Appearance (PNA)

Appendix VI. Methods for Performing Subjective Global Assessment

Appendix VII. Methods for Performing Anthropometry and Calculating Body Measurements and Reference Tables

Appendix VIII. Serum Transferrin and Bioelectrical Impedance Analysis

Appendix IX. Estimation of Glomerular Filtration Rate

Appendix X. Potential Uses for L-Carnitine in Maintenance Dialysis Patients

D. References (Adult Guidelines)

E. Index of Equations and Tables (Adult Guidelines)

6.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41:S1-S92, 2003 (suppl 3)  http://www.kidney.org/professionals/kdoqi/guidelines_lipids/index.htm

All Stages

Tables
Figures
Acronyms and Abbreviations
Work Group Membership
K/DOQI Advisory Board Members

Foreword

Abstract

Part 1. Introduction

Part 2. Assessment of Dyslipidemias

Part 3. Treating Dyslipidemias

Part 4. Research Recommendations

Part 5. Appendices

Biographical Sketches of Work Group Members

Acknowledgments

References

Disclaimer

7.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S202, 2003 (suppl 3)  http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm

All Stages

Tables
Figures
Algorithms
Acronyms and Abbreviations
Work Group Membership
Foreword
Introduction
Guideline Statements
Background
Methods for Analysis of Literature

Clinical Practice Guidelines

  • Guideline 1.   Evaluation of Calcium and Phosphorus Metabolism – CPG 1.4 is not adopted by VillageHealth DM due to new findings by KDIGO
  • Guideline 2.   Assessment of Bone Disease Associated With CKD
  • Guideline 3.   Evaluation of Serum Phosphorus Levels – CPG 3.2 is not adopted by VillageHealth DM due to new findings by KDIGO
  • Guideline 4.   Restriction of Dietary Phosphorus in Patients With CKD
  • Guideline 5.   Use of Phosphate Binders in CKD
  • Guideline 6.   Serum Calcium and Calcium-Phosphorus Product – CPG 6.5 is not adopted by VillageHealth DM due to new findings by KDIGO
  • Guideline 7.   Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients
  • Guideline 8.   Vitamin D Therapy in CKD Patients
    • Guideline 8A.   Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD
    • Guideline 8B.   Vitamin D Therapy in Patients on Dialysis (CKD Stage 5)
  • Guideline 9.   Dialysate Calcium Concentrations
  • Guideline 10.   ß2-Microglobulin Amyloidosis
  • Guideline 11.   Aluminum Overload and Toxicity in CKD
  • Guideline 12.   Treatment of Aluminum Toxicity
  • Guideline 13.   Treatment of Bone Disease in CKD
  • Guideline 14.   Parathyroidectomy in Patients With CKD
  • Guideline 15.   Metabolic Acidosis
  • Guideline 16.   Bone Disease in the Kidney Transplant Recipient

The Overall Approach to the Management of Bone Metabolism and Disease in CKD Patients

Biographical Sketches of Work Group Members

References

Complete Bibliography From Evidence Reports

Disclaimer

8.

National Kidney Foundation. K/DOQITM Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43:S1-S290, 2004 (suppl 1)  http://www.kidney.org/professionals/kdoqi/guidelines_bp/index.htm

All Stages

Tables - Tip
Figures - Tip
Acronyms and Abbreviations
Work Group Membership and Evidence Review Team
K/DOQI Advisory Board Members
Foreword
Executive Summary
Background

Clinical Practice Guidelines

  • Guideline 1.    Goals of Antihypertensive Therapy in CKD
  • Guideline 2.    Evaluation of Patients With CKD or Hypertension
  • Guideline 3.    Measurement of Blood Pressure in Adults
  • Guideline 4.    Evaluation for Renal Artery Disease
  • Guideline 5.    Education on Self-Management Behavior
  • Guideline 6.    Dietary and Other Therapeutic Lifestyle Changes in Adults
  • Guideline 7.    Pharmacological Therapy: Use of Antihypertensive Agents in CKD
  • Guideline 8.    Pharmacological Therapy: Diabetic Kidney Disease
  • Guideline 9.   Pharmacological Therapy: Nondiabetic Kidney Disease
  • Guideline 10.  Pharmacological Therapy: Kidney Disease in the Kidney Transplant Recipient
  • Guideline 11.   Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD
  • Guideline 12.   Use of Diuretics in CKD
  • Guideline 13.   Special Considerations in Children

Recommendations for Clinical Performance Measures

Appendices

  • Appendix 1: Methods Used for Guideline Development
  • Appendix 2: MEDLINE Search Strategies
  • Appendix 3: Technical Report on Ambulatory Blood Pressure Monitoring in CKD

Work Group Biographies

Acknowledgments

References

K/DOQI Disclaimer

9.

National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45:S1-S154, 2005 (suppl 3)  http://www.kidney.org/professionals/kdoqi/guidelines_cvd/index.htm

Stage 5

(on dialysis)

Tables
Figures
Acronyms and abbreviations
Work group members
K/DOQI advisory board members
Foreword
Overview of epidemiology of cardiovascular disease
Overview of epidemiology of cardiovascular disease in children

Section I. Guidelines on evaluation and management of cardiovascular diseases

Section II. Guidelines on management of cardiovascular risk factors

Section III. State of the science: novel and controversial topics in cardiovascular diseases

Intradialytic Hypotension
Biomarkers
Troponin
Inflammation
Oxidative Stress
Nutritional and Metabolic Factors
Body Weight and Management
Omega-3 Fatty Acids
Homocysteine
Lipoprotein(a) and Apolipoprotein(a) Polymorphism
Malnutrition
Risk Stratification
Overview of Risk Stratification
Family History and Genetics
Menopause
Preventive Foot Care in Diabetes
Aspirin

Methods for review of article
Work group biographies
Acknowledgment
References
Disclaimer

10.

National Kidney Foundation. KDOQI™ Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S1-S180, 2007 (suppl 2)  http://www.kidney.org/professionals/kdoqi/guideline_diabetes/

All Stages

Tables
Figures
Acronyms and Abbreviations
Work Group Membership
KDOQI Advisory Board Members
Foreword
Disclaimer

  1. EXECUTIVE SUMMARY
    • Executive Summary
  2. CLINICAL PRACTICE GUIDELINES
    • Background
    • Guideline 1: Screening and Diagnosis of Diabetic Kidney Disease
    • Guideline 2: Management of Hyperglycemia and General Diabetes Care in Chronic Kidney Disease – this CPG is not adopted by VillageHealth DM
    • Guideline 3: Management of Hypertension in Diabetes and Chronic Kidney Disease
    • Guideline 4: Management of Dyslipidemia in Diabetes and Chronic Kidney Disease
    • Guideline 5: Nutritional Management in Diabetes and Chronic Kidney Disease
  3. CLINICAL PRACTICE RECOMMENDATIONS
  4. RESEARCH RECOMMENDATIONS

APPENDICES

  • Appendix 1: Nutritional Management of Diabetes and Chronic Kidney Disease
  • Appendix 2: Methods for Evaluating Evidence

WORK GROUP BIOGRAPHIES, ACKNOWLEGMENTS, & REFERENCES

  • Work Group Biographies
  • Acknowledgments
  • References

11.

Renal Physicians Association Clinical Practice Guideline #2

Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis, February 2000

Stage 5

(on dialysis)

RPA Guideline #2 You must have access to VillageHealth Intranet to use this link

12.

Renal Physicians Association Clinical Practice Guideline #3; Appropriate Patient Preparation for Renal Replacement Therapy, October 2002

Stages 3-5

(not on dialysis)

Sections:

Counseling and Rehabilitation, page 55

Timing of Initiation for RRT, page 63

RPA Guideline #3 You must have access to VillageHealth Intranet to use this link 

13.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule:  United States, October 2007-September 2008. Ann Intern Med. 2007; 147:725-9.

All Stages

ACIP You must have access to VillageHealth Intranet to use this link 

14. 

FDA EPOGEN® (Epoetin alfa) FOR INJECTION. EPOGEN® package insert, FDA Approved: 11-19-08

All Stages

EPOGEN You must have access to VillageHealth Intranet to use this link

15. 

Suma Dronovalli, Basil Burney, George Bakris  Glycemic Control and Cardiovascular Disease in Chronic Kidney Disease. Current Diabetes Reports, Vol. 9, No. 3 (1 June 2009), pp. 243-248. 

All Stages

Glycemic You must have access to VillageHealth Intranet to use this link

16. 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney International 2009; 76 (Suppl 113): S1–S130.

All Stages

Tables and figures
Disclaimer
Work Group membership
KDIGO Board Members
Abbreviations and acronyms
Reference Keys
Abstract

 

Success Stories

" I am a 53-year-old man living in Riverside, CA who had a kidney ... more "
David
" I am the caregiver for my wife who had a stroke and cannot talk very ... more "
Vickie
" When I was in the hospital, my VillageHealth Nurse was my lifeline. ... more "
Eleanor
" The Key to Better Health gives me a place to go for information and ... more "
Nicholas
" I am a 62-year-old man who lives in San Bernardino, CA and I have ... more "
Robert
" I am a 60-year-old woman who lives in San Bernardino, CA and I have ... more "
Margaret
"

I am a 56-year-old man who lives in San Bernardino, CA ... more "

William
"

The Key to Better Health helps me feel better. My ... more "

Ann
"

I was blessed the day Key to Better Health first ... more "

Salvatore

Page 'Breadcrumb' Navigation: